Charlotte Dong Associate


Parle :  Anglais, Mandarin

Téléphone principal : +1 613-786-0217

Fax : +1 613-563-9869

Courriel : charlotte.dong@gowlingwlg.com

Télécharger vCard


Bureau principal :  Ottawa




Charlotte Dong

Charlotte Dong is an intellectual property lawyer in Gowling WLG’s Ottawa office. Her practice focuses primarily on intellectual property litigation, helping clients with patent, trademark and copyright matters. Charlotte is a member of the firm’s Life Sciences and Intellectual Property Litigation groups.

Charlotte has represented clients in patent infringement, validity and remedies litigation and has appeared before the Federal Court and the Federal Court of Appeal. She has experience with technical areas of biotechnology, mechanical engineering and electrical engineering.

Before joining Gowling WLG, Charlotte worked in research & development at a pharmaceutical company in the United States to develop new technologies and antibody therapeutics.

She holds a master of science in physiology, has been published in peer-reviewed journals, and has presented at international conferences.

Charlotte Dong et al., The intestinal epithelial insulin-like growth factor-1 receptor links glucagon-like peptide-2 action to gut barrier function.
Endocrinology, 155(2): 370-379 (2014).

Charlotte Dong and Patricia Brubaker, Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis.
Nature Reviews - Gastroenterology & Hepatology, 9: 705-715 (2012).

Monika Poreba, Charlotte Dong et al., Role of fatty acid transport protein 4 in oleic acid-induced glucagon-like peptide-1 secretion from murine intestinal L cells.
American Journal of Physiology – Endocrinology & Metabolism, 303: E899-907 (2012).

Actualités et ressources

Mandats représentatifs

dTechs v BC Hydro (T-227-17): counsel for BC Hydro in a patent infringement and validity trial involving theft detection in electricity grids

Seedlings v Pfizer (T-608-17; A-431-19; A-44-20): represented Seedlings in a patent infringement, validity and remedies proceeding involving auto-injectors (2019 FC 1396; 2020 FC 1; 2020 FC 505)

Bayer v Teva (T-1960-18; T-2093-18; T-435-19; T806-19): successfully represented Bayer on a Rule 220 motion (2019 FC 1370, aff’d 2020 FCA 71) (XARELTO®)